Hybrigenics receives €1.4 million to develop inecalcitol
This article was originally published in Scrip
Executive Summary
Hybrigenicshas received €1.4 million from OSEO, a French governmental development agency, to develop inecalcitol for prostrate cancer. The refundable subsidy will help the French functional proteomics firm and developer of cancer therapies to fund Phase II clinical trials through to their expected completion in mid-2009, and for regulatory requirements for authorising therapeutic efficacy studies. The company is conducting a Phase II tolerance trial of inecalcitol in combination with Sanofi-Aventis's Taxotere (docetaxel) for hormone-refractory prostate cancer. The oral dose of 300mg showed excellent tolerance, said Hybrigenics, and treatment with 600mg has just begun. The funding contributes 47.3% to total spending needed for the trial.